Regenxbio Inc (RGNX)

$8.53 -0.03 (-0.35%)
Market Cap 563.09M
Revenue (ttm) 170.44M
Net Income (ttm) -193.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -113.75%
Debt to Equity Ratio 0.00
Volume 1,029,100
Avg Vol 1,632,880
Day's Range N/A - N/A
Shares Out 66.01M
Stochastic %K 11%
Beta 0.94
Analysts Strong Sell
Price Target $24.42

Company Profile

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment...

Industry: Biotechnology
Sector: Healthcare
Phone: 240 552 8181
Address:
9804 Medical Center Drive, Rockville, United States
buymoremakemore
buymoremakemore Sep. 11 at 5:20 PM
$RGNX Nice mention in BioPharmaCatalyst newsletter today
0 · Reply
Cashmoneyt
Cashmoneyt Sep. 11 at 5:14 PM
$RGNX red everyday this stock is something else
0 · Reply
Ml55totoag
Ml55totoag Sep. 11 at 4:01 PM
$RGNX latest job opening.
0 · Reply
Find_the_Cure
Find_the_Cure Sep. 10 at 9:05 PM
$RGNX low volume price spikes here have often times failed lately.
0 · Reply
Teillbou
Teillbou Sep. 10 at 7:52 PM
$RGNX RGX-314 / SuraVec: I don't think the trial will be a failure, but I'm starting to worry that the results may not be clinically strong enough to support a compelling commercial opportunity. I checked AbbVie's job postings and don't see any obvious hiring or communication signals. Some roles appeared about a month ago but were closed without any obvious hires. By now they should have some internal data, so I'm wondering whether the pivotal results might be less impressive than the Phase 1/2 data. Any other signals I might be missing?
2 · Reply
rgnxrulez
rgnxrulez Sep. 10 at 7:11 PM
$RGNX just for fun, what do you think the SP will be at EoY? Needless to say, this year has NOT gone according to plan for RGNX (and for me). Let’s see what people think the last 3 months hold for us
0 · Reply
FUD_Slayer
FUD_Slayer Sep. 10 at 12:28 PM
Posting this for myself to come back and see who has seen the most gains in 6 months Cheers bulls $OSTX $ALT $ICU $RZLT $RGNX
1 · Reply
rando321456
rando321456 Sep. 9 at 11:06 PM
$RGNX $SLDB Reading through the transcript for Solid's call and I really think their CEO is such a joke. My read is that their NSAA results are mediocre and they're not sure the functional data is good enough for an AA path. I would also hazard a guess their expression levels got worse aswell. This slimeball is also subtlety trying to downplay their market size, by going from saying 100% of the market a few calls ago to saying they can only address up to 50% today(as I have pointed out). He's doing this to pivot market focus. At the rate things are going they are going to try to milk investors for as much as they can before putting out mediocre functional data and trying to talk it up.
2 · Reply
BioRich
BioRich Sep. 9 at 6:07 PM
$RGNX Legging up on this market red day. I'll take it. High hopes here and like how we're positioned. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money.
0 · Reply
Wolfman5960
Wolfman5960 Sep. 8 at 10:10 PM
$RGNX HHS announced the permanent CDER and CBER Directors. Michael Davis for CDER and Karim Mikhail for CBER. These were the current acting directors so looks like they just converted them into the permanent director roles. https://www.hhs.gov/press-room/hhs-announces-key-fda-leadership-selections.html Karim Mikhail's CBER has been showing flexibility lately so glad to see him in the permanent CBER role. Plus he's an industry guy and not from academia.
0 · Reply
Latest News on RGNX
REGENXBIO to Participate in Upcoming Investor Conferences

Sep 8, 2026, 7:05 AM EDT - 6 days ago

REGENXBIO to Participate in Upcoming Investor Conferences

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)

Aug 25, 2026, 12:53 PM EDT - 19 days ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)

Regenxbio price target lowered to $21 from $23 at H.C. Wainwright

2026-08-25T15:35:16.000Z - 19 days ago

Regenxbio price target lowered to $21 from $23 at H.C. Wainwright

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli

Aug 25, 2026, 7:05 AM EDT - 20 days ago

REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli

Regenxbio price target lowered to $29 from $32 at Baird

2026-08-25T10:25:26.000Z - 20 days ago

Regenxbio price target lowered to $29 from $32 at Baird

Regenxbio price target lowered to $32 from $45 at Clear Street

2026-08-25T08:15:13.000Z - 20 days ago

Regenxbio price target lowered to $32 from $45 at Clear Street

RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO Inc. Following Clinical Hold

Aug 24, 2026, 2:18 PM EDT - 20 days ago

RGNX Investor Notice: Johnson Fistel Investigates REGENXBIO Inc. Following Clinical Hold

BofA says Regenxbio’s MPS setback ‘disappointing,’ larger catalysts intact

2026-08-24T15:30:08.000Z - 20 days ago

BofA says Regenxbio’s MPS setback ‘disappointing,’ larger catalysts intact

Morning Movers: Regenxbio sinks following clinical hold on RGX-121

2026-08-24T13:00:24.000Z - 21 days ago

Morning Movers: Regenxbio sinks following clinical hold on RGX-121

BABA ERAS GGR GOOS NSSC PDD XPEV

Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial

Aug 24, 2026, 8:39 AM EDT - 21 days ago

Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial

Regenxbio to resume trading at 7:25 am ET

2026-08-24T11:25:11.000Z - 21 days ago

Regenxbio to resume trading at 7:25 am ET

FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome

Aug 24, 2026, 7:25 AM EDT - 21 days ago

FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome

Regenxbio reports FDA placed clinical hold on RGX-121

2026-08-24T11:20:06.000Z - 21 days ago

Regenxbio reports FDA placed clinical hold on RGX-121

REGENXBIO Announces Regulatory Update on RGX-121 for MPS II

Aug 24, 2026, 7:05 AM EDT - 21 days ago

REGENXBIO Announces Regulatory Update on RGX-121 for MPS II

Regenxbio price target lowered to $23 from $26 at H.C. Wainwright

2026-08-10T10:21:13.000Z - 5 weeks ago

Regenxbio price target lowered to $23 from $26 at H.C. Wainwright

Regenxbio price target raised to $18 from $16 at Morgan Stanley

2026-08-07T13:51:02.000Z - 5 weeks ago

Regenxbio price target raised to $18 from $16 at Morgan Stanley

Regenxbio downgraded to Equal Weight from Overweight at Barclays

2026-08-07T09:15:51.000Z - 5 weeks ago

Regenxbio downgraded to Equal Weight from Overweight at Barclays

REGENXBIO Earnings Call Transcript: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 5 weeks ago

REGENXBIO Earnings Call Transcript: Q2 2026

REGENXBIO Earnings release: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 5 weeks ago

REGENXBIO Earnings release: Q2 2026

REGENXBIO Quarterly report: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 5 weeks ago

REGENXBIO Quarterly report: Q2 2026

Regenxbio reports Q2 EPS 43c vs. ($1.38) last year

2026-08-06T11:33:11.000Z - 5 weeks ago

Regenxbio reports Q2 EPS 43c vs. ($1.38) last year

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

Aug 6, 2026, 7:05 AM EDT - 5 weeks ago

REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights

REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights

Aug 3, 2026, 7:05 AM EDT - 6 weeks ago

REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights

Regenxbio presents long-term data for surabgene lomparvovec

2026-07-19T15:45:15.000Z - 1 month ago

Regenxbio presents long-term data for surabgene lomparvovec

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

Jul 18, 2026, 2:55 PM EDT - 1 month ago

REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting

Regenxbio 10M share Spot Secondary priced at $9.00

2026-07-17T11:05:39.000Z - 1 month ago

Regenxbio 10M share Spot Secondary priced at $9.00

REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants

Jul 17, 2026, 7:00 AM EDT - 1 month ago

REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants

Regenxbio announces $100M common stock offering

2026-07-16T20:30:11.000Z - 1 month ago

Regenxbio announces $100M common stock offering

REGENXBIO Announces Proposed Public Offering of Common Stock

Jul 16, 2026, 4:26 PM EDT - 1 month ago

REGENXBIO Announces Proposed Public Offering of Common Stock

Regenxbio says first patient dosed in Phase IIb/III NAAVIGATE trial

2026-06-29T11:20:21.000Z - 2 months ago

Regenxbio says first patient dosed in Phase IIb/III NAAVIGATE trial

ABBV

REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone

Jun 29, 2026, 7:05 AM EDT - 2 months ago

REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone

Regenxbio completes dosing in confirmatory study of RGX-202

2026-06-24T11:10:54.000Z - 2 months ago

Regenxbio completes dosing in confirmatory study of RGX-202

REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026

Jun 24, 2026, 7:05 AM EDT - 2 months ago

REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026

Regenxbio price target raised to $32 from $27 at Baird

2026-06-23T10:44:38.000Z - 2 months ago

Regenxbio price target raised to $32 from $27 at Baird

REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II

Jun 22, 2026, 7:30 AM EDT - 2 months ago

REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II

FDA to reverse rejection of Regenxbio's rare-disease drug, WSJ reports

Jun 22, 2026, 7:01 AM EDT - 2 months ago

FDA to reverse rejection of Regenxbio's rare-disease drug, WSJ reports

FDA Will Reverse Rejection of Third Rare-Disease Drug, Regenxbio Says

Jun 22, 2026, 6:30 AM EDT - 2 months ago

FDA Will Reverse Rejection of Third Rare-Disease Drug, Regenxbio Says

REGENXBIO Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 20, 2026, 9:30 AM EDT - 3 months ago

REGENXBIO Transcript: RBC Capital Markets Global Healthcare Conference 2026

REGENXBIO Earnings release: Q1 2026

May 14, 2026, 9:30 AM EDT - 4 months ago

REGENXBIO Earnings release: Q1 2026

REGENXBIO Quarterly report: Q1 2026

May 14, 2026, 9:30 AM EDT - 4 months ago

REGENXBIO Quarterly report: Q1 2026

REGENXBIO Transcript: Study result

May 14, 2026, 8:00 AM EDT - 4 months ago

REGENXBIO Transcript: Study result

REGENXBIO Press release: Study result

May 14, 2026, 8:00 AM EDT - 4 months ago

REGENXBIO Press release: Study result

REGENXBIO Slides: Study result

May 14, 2026, 8:00 AM EDT - 4 months ago

REGENXBIO Slides: Study result

REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights

May 14, 2026, 7:10 AM EDT - 4 months ago

REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights

Regenxbio's muscle disorder therapy meets main goal in late-stage study

May 14, 2026, 7:04 AM EDT - 4 months ago

Regenxbio's muscle disorder therapy meets main goal in late-stage study

REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202

May 14, 2026, 7:00 AM EDT - 4 months ago

REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

May 7, 2026, 7:05 AM EDT - 4 months ago

REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting

REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy

May 6, 2026, 7:05 AM EDT - 4 months ago

REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy

REGENXBIO Proxy statement: Proxy filing

Apr 14, 2026, 8:00 AM EDT - 5 months ago

REGENXBIO Proxy statement: Proxy filing

REGENXBIO Proxy statement: Proxy filing

Apr 14, 2026, 8:00 AM EDT - 5 months ago

REGENXBIO Proxy statement: Proxy filing

REGENXBIO Proxy statement: Proxy filing

Apr 3, 2026, 8:00 AM EDT - 5 months ago

REGENXBIO Proxy statement: Proxy filing

SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD

Mar 26, 2026, 9:00 AM EDT - 5 months ago

SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD

Regenxbio's Duchenne gene therapy shows improved muscle function in trial

Mar 11, 2026, 12:00 PM EDT - 6 months ago

Regenxbio's Duchenne gene therapy shows improved muscle function in trial

REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

Mar 11, 2026, 11:45 AM EDT - 6 months ago

REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

REGENXBIO Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 10, 2026, 1:30 PM EDT - 6 months ago

REGENXBIO Transcript: Barclays 28th Annual Global Healthcare Conference

REGENXBIO Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 9:20 AM EDT - 6 months ago

REGENXBIO Transcript: Leerink Global Healthcare Conference 2026

FDA reversals leave investors worrying about the fates of other experimental drugs

Mar 6, 2026, 11:33 AM EST - 6 months ago

FDA reversals leave investors worrying about the fates of other experimental drugs

DNLI MRNA WVE

RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST

Mar 5, 2026, 2:25 PM EST - 6 months ago

RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST

REGENXBIO Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:00 AM EST - 6 months ago

REGENXBIO Earnings Call Transcript: Q4 2025

REGENXBIO Annual report: Q4 2025

Mar 5, 2026, 8:00 AM EST - 6 months ago

REGENXBIO Annual report: Q4 2025

REGENXBIO Earnings release: Q4 2025

Mar 5, 2026, 8:00 AM EST - 6 months ago

REGENXBIO Earnings release: Q4 2025

REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Mar 5, 2026, 7:05 AM EST - 6 months ago

REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Mar 4, 2026, 7:05 AM EST - 6 months ago

REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

REGENXBIO, Inc. Stockholders Have Rights - Stockholders Who Lost Money Investing in RGNX Should Contact Robbins LLP for Information About Recovering Their Losses

Mar 2, 2026, 5:58 PM EST - 6 months ago

REGENXBIO, Inc. Stockholders Have Rights - Stockholders Who Lost Money Investing in RGNX Should Contact Robbins LLP for Information About Recovering Their Losses

REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Feb 25, 2026, 7:05 AM EST - 6 months ago

REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

US FDA declines to approve Regenxbio's rare disease drug

Feb 9, 2026, 4:13 PM EST - 7 months ago

US FDA declines to approve Regenxbio's rare disease drug

REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II

Feb 9, 2026, 4:05 PM EST - 7 months ago

REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II

Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA Action

Jan 29, 2026, 6:06 PM EST - 7 months ago

Investigation into Regenxbio: Questions Arise Over Disclosure Completeness Prior to FDA Action

US FDA places clinical hold on Regenxbio's gene therapy trials

Jan 28, 2026, 7:46 AM EST - 7 months ago

US FDA places clinical hold on Regenxbio's gene therapy trials

buymoremakemore
buymoremakemore Sep. 11 at 5:20 PM
$RGNX Nice mention in BioPharmaCatalyst newsletter today
0 · Reply
Cashmoneyt
Cashmoneyt Sep. 11 at 5:14 PM
$RGNX red everyday this stock is something else
0 · Reply
Ml55totoag
Ml55totoag Sep. 11 at 4:01 PM
$RGNX latest job opening.
0 · Reply
Find_the_Cure
Find_the_Cure Sep. 10 at 9:05 PM
$RGNX low volume price spikes here have often times failed lately.
0 · Reply
Teillbou
Teillbou Sep. 10 at 7:52 PM
$RGNX RGX-314 / SuraVec: I don't think the trial will be a failure, but I'm starting to worry that the results may not be clinically strong enough to support a compelling commercial opportunity. I checked AbbVie's job postings and don't see any obvious hiring or communication signals. Some roles appeared about a month ago but were closed without any obvious hires. By now they should have some internal data, so I'm wondering whether the pivotal results might be less impressive than the Phase 1/2 data. Any other signals I might be missing?
2 · Reply
rgnxrulez
rgnxrulez Sep. 10 at 7:11 PM
$RGNX just for fun, what do you think the SP will be at EoY? Needless to say, this year has NOT gone according to plan for RGNX (and for me). Let’s see what people think the last 3 months hold for us
0 · Reply
FUD_Slayer
FUD_Slayer Sep. 10 at 12:28 PM
Posting this for myself to come back and see who has seen the most gains in 6 months Cheers bulls $OSTX $ALT $ICU $RZLT $RGNX
1 · Reply
rando321456
rando321456 Sep. 9 at 11:06 PM
$RGNX $SLDB Reading through the transcript for Solid's call and I really think their CEO is such a joke. My read is that their NSAA results are mediocre and they're not sure the functional data is good enough for an AA path. I would also hazard a guess their expression levels got worse aswell. This slimeball is also subtlety trying to downplay their market size, by going from saying 100% of the market a few calls ago to saying they can only address up to 50% today(as I have pointed out). He's doing this to pivot market focus. At the rate things are going they are going to try to milk investors for as much as they can before putting out mediocre functional data and trying to talk it up.
2 · Reply
BioRich
BioRich Sep. 9 at 6:07 PM
$RGNX Legging up on this market red day. I'll take it. High hopes here and like how we're positioned. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money.
0 · Reply
Wolfman5960
Wolfman5960 Sep. 8 at 10:10 PM
$RGNX HHS announced the permanent CDER and CBER Directors. Michael Davis for CDER and Karim Mikhail for CBER. These were the current acting directors so looks like they just converted them into the permanent director roles. https://www.hhs.gov/press-room/hhs-announces-key-fda-leadership-selections.html Karim Mikhail's CBER has been showing flexibility lately so glad to see him in the permanent CBER role. Plus he's an industry guy and not from academia.
0 · Reply
maphere
maphere Sep. 8 at 7:30 PM
$RGNX Regenxbio presenting at the World Muscle Society on Oct. 3rd Saturday 3 October 2026 Clinical trial updates: RGX-202, a phase I/II/III investigational gene therapy for the treatment of Duchenne muscular dystrophy Steve Pakola, Aravindhan Veerapandiyan, Crystal Proud, Nancy Kuntz, Amy Harper, Susan Iannaccone, Carolina Tesi-Rocha1, Erika Finanger, Cuixia Tian, Han Phan, Eleonora D’ambrosio, Dimah Saade, Jahannaz Dastgir, Regenxbio RGX-202 Study Team, Koji Takahashi, Olivier Danos 1Stanford School of Medicine, Stanford, United States https://www.wms2026.com/file/5e8569aa-8713-4e49-8735-452b656917c3/WMS2026%20Full%20Programme%20%28070926%29.pdf
0 · Reply
rando321456
rando321456 Sep. 8 at 5:26 PM
$RGNX With the failure of Avidity's asset in dm1 today it reinforces my belief that exon 44 was just more amenable to skipping and resulted in their technology showing decent functional outcomes for their other lead asset. I still continue to believe that RGX-202 is the best therapy for dmd until we figure out how to do what precision bioscience is doing better or other genetic schemes to get closer to full length dystrophin.
1 · Reply
Wolfman5960
Wolfman5960 Sep. 8 at 1:25 PM
$RGNX Regenx will be participating in two investor conferences this month: https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-participate-upcoming-investor-conferences-27 Baird Global Healthcare Conference Tuesday, September 15th at 8:30am ET Morgan Stanley Global Healthcare Conference Wednesday, September 16th at 8:30am ET
1 · Reply
Teillbou
Teillbou Sep. 4 at 5:27 PM
$RGNX A good hiring position signal today for RGX-202 but does not clarify FDA position on the submission. Director, Market Development - Southeast Region https://www.linkedin.com/jobs/view/4463357111/
2 · Reply
Redposition
Redposition Sep. 4 at 3:06 PM
$RGNX Not looking good 🤔
1 · Reply
rando321456
rando321456 Sep. 4 at 2:44 AM
$RGNX 3 more sites on the NPDR trial, up to 30 now
0 · Reply
Teillbou
Teillbou Sep. 3 at 7:45 PM
$RGNX - sold 1/3 for ULTRAGENYX RARE Too good of an opportunity to pass up, and I want to de-risk. RGX-202 communication remains a concern. The people leading the program are very quiet on LinkedIn, and despite the job listings for months for MSL, they still haven't hired them. My guess: FDA hasn't given them a clear enough green light for the BLA yet, and they're trying to force it.
1 · Reply
DarkOrb
DarkOrb Sep. 3 at 5:53 PM
$RGNX Maybe down today on sympathy with RARE blowup.
1 · Reply
BioRich
BioRich Sep. 3 at 3:19 PM
$RGNX Looking to turn after the initial 5% loss. Should close green (or close to it). Longer term, continued strength seen. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers!
0 · Reply
Ml55totoag
Ml55totoag Sep. 2 at 9:47 PM
$RGNX DTX-401 pdufa august 23.
1 · Reply
BenTheDo
BenTheDo Sep. 1 at 3:16 PM
$RGNX Shouldn't their DMD BLA be coming out any day now?
3 · Reply